By: Marcia Frellick
On Oct. 29, the U.S. Food and Drug Administration (FDA) expanded its approval of liquid methotrexate (Jylamvo) to include pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis, according to a news release from Shorla Oncology.